Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Agfa Props Cardio Imaging Platform With Heartlab Purchase, Gains 250 Sites

This article was originally published in The Gray Sheet

Executive Summary

Heartlab CEO Robert Petrocelli, a physicist and computer expert, will head Agfa's cardiology business following a $132.5 mil. acquisition by the diversified imaging giant

You may also be interested in...


IMPAX picture archiving and communications system (PACS) maker Agfa acquires privately held, Waterloo, Ontario-based OEM software supplier Mitra. Mortsel, Belgium-based diversified imaging firm Agfa-Gevaert N.V.'s Agfa HealthCare unit notes that Mitra "has played an integral role in the development and success of Agfa's IMPAX PACS solutions for the past ten years" and "this next step in the relationship is the best way to ensure that the mission we have pursued in the past is continued, enhanced and expanded." Terms of the deal were not disclosed...

QUOTED. 3 April 2020. Minetta Liu.

Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.

Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals

Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts